Funding

• NIH/NCI R01CA142859 (PI: Conaway). Designs for phase I trials of combinations of agents. 2010-2013.
• NIH/NCI R01CA142859 (PI: Conaway). Designs for phase I trials in heterogeneous groups. 2014-2019.
• NIH/NCI K25CA181638 (PI: Wages). Phase I designs for combined immunotherapies in cancer. 2014-2019.

• NIH/NCI R03CA238966 (PI: Wages). Dose-finding designs for adoptive cell therapy trials. 2019-2021.
• NIH/NCI R01CA247932 (PI: Wages). Dose finding designs for late-onset toxicities. 2021-2024.